ABBV-318

TargetMol
Product Code: TAR-T62000
Supplier: TargetMol
CodeSizePrice
TAR-T62000-1mg1mg£148.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T62000-5mg5mg£269.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T62000-1mL1 mL * 10 mM (in DMSO)£289.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T62000-10mg10mg£369.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T62000-25mg25mg£576.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T62000-50mg50mg£790.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T62000-100mg100mg£1,050.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T62000-500mg500mg£2,038.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C

Images

1 / 1

Further Information

Bioactivity:
ABBV-318 can be used as small molecule Nav1.7/Nav1.8 blockers for the treatment of pain, with IC50 values of 2.8 uM for hNav1.7 and 3.8 uM for hNav1.8. ABBV-318 can be used to study pain-related disorders.
CAS:
1802848-94-7
Formula:
C20H15F4N3O2
Molecular Weight:
405.35
Purity:
0.9961
SMILES:
O(C1=CC2=C(N=C(C(=O)N3CC[C@@H](F)C3)C=C2)C=C1)C4=CC=C(C(F)(F)F)C=N4

References

Hafler BP. CLINICAL PROGRESS IN INHERITED RETINAL DEGENERATIONS: GENE THERAPY CLINICAL TRIALS AND ADVANCES IN GENETIC SEQUENCING. Retina. 2017 ; 37(3):417-423. Patel MV, et al. Discovery of (R)-(3-fluoropyrrolidin-1-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)quinolin-2-yl)methanone (ABBV-318) and analogs as small molecule Nav1.7/ Nav1.8 blockers for the treatment of pain. Bioorg Med Chem. 2022 ; 63:116743. Verma IC, et al. Genetic Testing in Pediatric Ophthalmology. Indian J Pediatr. 2018 ; 85(3):228-236. Poulsen SB, et al. Sodium-glucose cotransport. Curr Opin Nephrol Hypertens. 2015 ; 24(5):463-469. Koepsell H. The Na(+)-D-glucose cotransporters SGLT1 and SGLT2 are targets for the treatment of diabetes and cancer. Pharmacol Ther. 2017 ; 170:148-165.